According to FutureWise analysis the market for High Throughput Screening in 2023 was US$ 18 billion, and is expected to reach US$ 33 billion by 2031 at a CAGR of 8%.
High-throughput screening (HTS) is an innovative drug discovery technique that facilitates the automated assessment of numerous chemical and biological molecules for specific biological targets. In the pharmaceutical industry, HTS is commonly employed to swiftly evaluate the biological or biochemical activities of a wide array of compounds. This process relies on robotics and automation to enhance efficiency.
By utilizing high-throughput screening, researchers can conduct millions of genetic, chemical, or pharmacological experiments in a fraction of the time it would traditionally take, employing robotics, liquid handling equipment, data processing software, and highly sensitive detectors.
In recent years, the availability of high-throughput screening facilities has expanded significantly. These range from extensive molecular libraries and probe center networks to smaller university-based screening facilities. These institutions implement both traditional and advanced assay technologies to facilitate primary and secondary screening campaigns, thus providing a comprehensive approach to probe discovery.
The growth of the high-throughput screening market is driven by the increasing demand for expedited drug development, which ultimately reduces the time required to bring new medications to market. Additionally, government funding for new technologies, including CRISPR-Cas9, RNA interference (RNAi), and artificial intelligence, has contributed to this trend. Moreover, factors such as rising healthcare expenditures, higher disposable incomes, and increasing awareness within end-use industries are positively impacting the high-throughput screening market.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=8921%20type=requestsample
High Throughput Screening Market Segmentation:
By Products and Services
· Products
o Reagents and Assay Kits
o Instruments
o Software
· Services
By Technology
· Cell-Based Assays
o Cell Proliferation Assays
o Cell Viability Assays
o Cell Cytotoxicity Assays
o Cell Death Assays
o Other Cell-Based Assays
· Lab-on-a-Chips
o PDMS
o Thermopolymers
o Glass
o Silicon
o Paper
· Ultra high throughput Screening
o Chip-based Screening
o Micro-channel Flow Systems
o Plateless Systems
o Others
· Label-Free Technology
o SPR
o ITC
o Others
By Application
· Drug Discovery
o Medicinal Chemistry
o Biology Services
o Drug Metabolism and Pharmacokinetics (DMPK)
· Chemical Biology Programs
o Cellular Biological Simulation
o Disease Modelling
o Preclinical Drug Development
o Clinical Trials
· Cell Organ-Based Screening
o Drug Discovery
o Academic Research
· Biochemical Screening
o Blood and Blood –based Products
o Vaccines and Therapeutics
o Stem Cells
· Biological Active Compound Screening
o Target Identification
o Primary Screening
o Toxicology
· Genomics
o Diagnostic Application
o Precision Medicine
· Proteomics
o Drug Diagnostics
o Precision Medicine
· Compound Profiling
o Drug Discovery
o Cancer/Tumor Profiling
o Toxicology
By Detection Method
· Mass Spectrometry
o
